US cell and gene therapy CDMO Andelyn Biosciences has announced the signing of a new collaboration agreement to establish a strategic manufacturing bridge between the United States and Asia-Pacific (APAC) regions to streamline the global delivery of gene therapies.
The pair said in a statement that the new partnership will combine their industry-leading GMO manufacturing facilities, technical expertise and regional networks to fast-track the development, manufacturing and global expansion of client programmes that deliver next-generation gene therapies to patients worldwide.
The partnership will streamline a 'dual hemisphere' workflow by connecting US and APAC manufacturing hubs, simplifying international expansion by removing regulatory and logistical challenges.
Enabling in-country manufacturing for local clinical trials will ensure regional supply chains meet the needs of local patients, reducing lead times and accelerating commercialisation.
Wade Macedone, CEO at Andelyn, said: "Our partnership with ENCell is a powerful step forward in Andelyn's mission to help bring life-saving therapies to patients worldwide."
By joining forces with such a respected leader in South Korea, we are not just expanding our global footprint; we are leveraging our unique strengths to deliver a truly seamless international manufacturing network.
"This collaboration reinforces our shared leadership in the cell and gene therapy space and ensures that, together, we can support our clients with the expertise and scale needed to deliver the next generation of medicines on a global stage."
Dr Jong Wook Chang, CEO of ENCell, added: "This partnership with Andelyn represents a significant step in expanding the global CGT ecosystem."
By combining Andelyn's expertise in viral vector development and cGMP manufacturing with ENCell's clinical and manufacturing capabilities across APAC, we are establishing a seamless manufacturing platform connecting the United States and Asia-Pacific.
"Together, we will enable more efficient development and scalable production of gene therapies, supporting our clients from early-stage development through global clinical trials and commercialisation."
